Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.
Benjamin J SolomonGeoffrey LiuEnriqueta Felip FontTony S K MokRoss Andrew SooJulien MazieresAlice T ShawFilippo de MarinisYasushi GotoYi-Long WuDong Wan KimJean-Francois MartiniRossella MessinaJolanda PaoliniAnna PolliDespina ThomaidouFrancesca ToffalorioTodd M BauerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
-positive NSCLC and set a new benchmark for targeted therapies in cancer.